QTNT
Quotient Limited
$0.38
Earnings Summary
Revenue | $10.17Mn |
Net Profits | $-44.82Mn |
Net Profit Margins | -440.63% |
Highlights
Quotient Limited ’s revenue jumped 16.24% since last year same period to $10.17Mn in the Q4 2021. On a quarterly growth basis, Quotient Limited has generated 7.45% jump in its revenue since last 3-months.
Quotient Limited ’s net profit fell -50.62% since last year same period to $-44.82Mn in the Q4 2021. On a quarterly growth basis, Quotient Limited has generated -65.36% fall in its net profits since last 3-months.
Quotient Limited ’s net profit margin fell -29.58% since last year same period to -440.63% in the Q4 2021. On a quarterly growth basis, Quotient Limited has generated -53.9% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Quotient Limited post its latest quarter earnings
EPS Estimate Current Quarter | -4.4 |
EPS Estimate Current Year | -4.4 |
Highlights
Quotient Limited ’s earning per share (EPS) estimates for the current quarter stand at -4.4 - a 53.34% jump from last quarter’s estimates.
Quotient Limited ’s earning per share (EPS) estimates for the current year stand at -4.4.
Key Ratios
Key ratios of the Quotient Limited post its Q4 2022 earnings
Earning Per Share (EPS) | 0 |
Highlights
Quotient Limited ’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the Quotient Limited has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-11-06 | -0.4 | -0.53 | -32.5% |
2019-02-05 | -0.45 | -0.46 | -2.22% |
2018-08-07 | -0.41 | -0.55 | -34.15% |
2018-05-30 | -0.48 | -0.44 | 8.33% |
Company Information
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
Organisation | Quotient Limited |
Headquarters | Business Park Terre Bonne, Eysins, Switzerland, 1262 |
Employees | 450 |
Industry | Health Technology |
CEO | Franz Walt |
